James F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 220,230 shares of the firm’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $3.38, for a total value of $744,377.40. Following the sale, the chief executive officer now directly owns 3,194,583 shares in the company, valued at approximately $10,797,690.54. This represents a 6.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Checkpoint Therapeutics Price Performance

Shares of Checkpoint Therapeutics stock opened at $3.75 on Friday. The firm has a market cap of $183.12 million, a price-to-earnings ratio of -2.04 and a beta of 1.34. The stock’s 50-day moving average is $3.59 and its 200-day moving average is $2.71. Checkpoint Therapeutics, Inc. has a one year low of $1.38 and a one year high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). On average, equities analysts expect that Checkpoint Therapeutics, Inc. will post -0.91 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on CKPT. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Lake Street Capital raised their price objective on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, December 16th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. B. Riley Wealth Advisors Inc. increased its stake in Checkpoint Therapeutics by 366.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after buying an additional 180,050 shares during the last quarter. PVG Asset Management Corp bought a new position in shares of Checkpoint Therapeutics in the 2nd quarter valued at about $295,000. Geode Capital Management LLC increased its position in shares of Checkpoint Therapeutics by 41.2% in the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after acquiring an additional 124,787 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Checkpoint Therapeutics by 160.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after acquiring an additional 80,000 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in Checkpoint Therapeutics during the third quarter valued at approximately $148,000. Institutional investors and hedge funds own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.